VitaNova Life Sciences sets 1-for-3 reverse split

VitaNova Life Sciences Corporation, formerly Yijia Group Corp., reports that its corporate name change and a reverse stock split have now been cleared for trading purposes.

Rhea-AI Filing Summary

VitaNova Life Sciences Corporation, formerly Yijia Group Corp., reports that its corporate name change and a reverse stock split have now been cleared for trading purposes. The Certificate of Amendment filed in Nevada on January 9, 2026 changed the name to VitaNova Life Sciences Corporation and implemented a 1‑for‑3 reverse stock split, so each stockholder receives one share for every three previously held.

FINRA has completed its review, and both the name change and reverse split take effect on the OTC Pink marketplace as of January 27, 2026. The company’s common stock will trade under the symbol YJGJD for 20 trading days beginning January 27, 2026, after which the ticker will change to VNOV. The company has also obtained a new CUSIP number, 98585W403. The company states that no action is required by current stockholders in relation to these changes.

Insights

Equity structure and corporate actions analyst

Name change and 1-for-3 reverse split become effective for trading.

The company, now called VitaNova Life Sciences Corporation, has implemented a 1‑for‑3 reverse stock split via a Nevada Certificate of Amendment. This consolidates every three existing common shares into one share without changing aggregate ownership percentages.

FINRA has completed its review so that, from January 27, 2026, trading on the OTC Pink marketplace reflects both the new name and post‑split share count. The temporary symbol will be YJGJD for 20 trading days, followed by the new ticker VNOV.

The company also reports a new common stock CUSIP, 98585W403, aligning security identifiers with the name change and reverse split. The company notes that no action is required by current stockholders, so mechanics such as share consolidation and symbol change are expected to be handled through standard brokerage and transfer agent processes.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What corporate changes did VitaNova Life Sciences (YJGJ) disclose in this 8-K?

VitaNova Life Sciences disclosed that it changed its corporate name from Yijia Group Corp. and implemented a 1-for-3 reverse stock split via a Certificate of Amendment filed in Nevada, with both actions now recognized for trading on the OTC Pink marketplace.

When does the 1-for-3 reverse stock split for VitaNova Life Sciences (YJGJ) take effect for trading?

The 1-for-3 reverse stock split, effectuated on January 9, 2026 under a Nevada Certificate of Amendment, becomes effective for trading on the OTC Pink marketplace on January 27, 2026, following completion of FINRA’s review of the reverse split.

How will the ticker symbol for VitaNova Life Sciences (YJGJ) change after the reverse split?

The common stock will trade as YJGJD for 20 trading days beginning January 27, 2026, reflecting the reverse split. After that period, the company expects its trading symbol to change to VNOV, aligning the ticker with the new VitaNova Life Sciences Corporation name.

What is the new CUSIP for VitaNova Life Sciences Corporation common stock?

The company obtained a new CUSIP number, 98585W403, for its common stock in connection with the name change and 1-for-3 reverse stock split. This new identifier helps brokers and clearing systems correctly track and settle trades in the post-split VitaNova Life Sciences shares.

Do VitaNova Life Sciences (YJGJ) stockholders need to take any action because of the name change and reverse split?

The company states that no action is required by current stockholders regarding the name change, 1-for-3 reverse split, or new ticker. Brokerage firms and the transfer agent are expected to handle share consolidation and updated identifiers automatically in investor accounts.

Who approved the reverse stock split for VitaNova Life Sciences (YJGJ) and at what ratio?

The company reports that its Board of Directors and a majority of holders of issued and outstanding common stock approved a reverse stock split. The Board then set the ratio at 1-for-3, so each stockholder receives one share for every three shares previously held.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:47 PM Learn about SEC filing dates

false 0001699709 0001699709 2026-01-27 2026-01-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): January 27, 2026

VitaNova Life Sciences Corporation

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-218733		35-2583762
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

39 E Broadway, Suite 603, New York, NY 10002

(Address of principal office)

+1-516-886-8888

(Registrant’s telephone number, including area code)

Yijia Group Corp.

(Former Name or former address if changed from last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		YJGJD		OTC Pink Sheets

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Item 8.01 Other Events.

As previously reported on the Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 7, 2025 and January 13, 2026, respectively, Yijia Group Corp. (the “Company”) proposed to change the name of the Company to VitaNova Life Sciences Corporation (the “Name Change”), and the Name Change was effectuated on January 9, 2026, through a Certificate of Amendment to the Articles of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Nevada. As of the date of this Current Report on Form 8-K (this “Report”), the Financial Industry Regulatory Authority (“FINRA”) has completed its review of the Name Change and has announced that the Name Change will be reflected for purposes of trading on the OTC Pink marketplace as of January 27, 2026.

As previously reported, the Company also proposed to effect a reverse stock split at a ratio within the range from 1-for-2 to 1-for-3, which was approved by the Company’s Board of Directors (the “Board”) and a majority of the holders of the Company’s issued and outstanding shares of common stock. The Board further approved the reverse stock split to be effectuated at the ratio of 1-for-3, such that each holder of common stock of the Company will receive one (1) share of common stock for every three (3) shares of common stock held (the “Reverse Split”). The Certificate of Amendment also effectuated the Reverse Split on January 9, 2026. As of the date of this Report, FINRA has completed its review of the Reverse Split and has announced that the Reverse Split will be given effect for the purposes of trading on the OTC Pink marketplace as of January 27, 2026.

In connection with the Name Change, the Company has requested that FINRA change the ticker symbol of its common stock to “VNOV” (the “New Ticker”). The Company’s common stock will continue to trade under the symbol of “YJGJ,” with the letter “D” added to the end of the trading symbol for a period of 20 trading days beginning on January 27, 2026, after which the Company’s trading symbol will be changed to the New Ticker. The Company has also obtained a new CUSIP number for its common stock in connection with the Name Change and the Reverse Split, which is 98585W403.

No action is required by current stockholders in relation to the announcement of the Name Change, Reverse Split, and New Ticker.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit		Description
3.1		Certificate of Amendment, dated January 9, 2026*
104		Cover Page Interactive File (embedded within the Inline XBRL document)

*Previously filed as exhibits to the Company’s Current Report as filed with the SEC on January 13, 2026.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 27, 2026

VitaNova Life Sciences Corporation
By:	/s/ Qiuping Lu
	Qiuping Lu
	Chief Executive Officer and Director (Principal Executive Officer)

3